P
Profound Therapeutics
Pioneering the expanded human proteome to reveal a universe of new medicines
About Profound Therapeutics
ProFound Therapeutics is a biotech startup that operates in the field of genomics and proteomics. The company's primary focus is on the discovery and analysis of proteins, which are the building blocks of life and play a crucial role in the functioning of our bodies. ProFound's innovative approach challenges the traditional understanding of the human proteome, which is the entire set of proteins that can be expressed by the genetic material in humans.
The company's research has led to the discovery of tens of thousands of previously undiscovered proteins. By understanding these proteins and their functions, ProFound aims to develop new therapeutic targets for a multitude of diseases, thereby revolutionizing the field of biomedicine.
ProFound's business model is centered around the application of advanced technology and biological insights to discover and analyze proteins. The company then leverages this knowledge to develop breakthrough medicines. This approach opens up a new world of therapeutic possibilities and has the potential to usher in a new era in biomedicine.
ProFound's clients are likely to be pharmaceutical and biotech companies looking for new therapeutic targets and treatments. The company operates in the rapidly growing genomics market, which is expected to reach $35.7 billion by 2024.
In terms of revenue, ProFound likely makes money by licensing its discoveries to pharmaceutical companies, who then develop and market the resulting drugs. The company may also generate revenue through partnerships, research grants, and potentially through the direct sale of any drugs it develops.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- Cambridge, United States
- Employees
- 51
- Open positions
- None listed
- Dealroom signal
- 86.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | May 2022 | $75M | $300M | Flagship Pioneering | ↗ |
Growth signals
Latest recorded traffic for Profound Therapeutics is 3.5K monthly website visits, down 7.9% over the last three months. Profound Therapeutics's team grew 24.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Profound Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Profound Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







